You are here



15 April 2011: The Board of Directors of NorDiag ASA calls for the Annual General Meeting of NorDiag to be held on Monday 9 May 2011 at 10:00 hours (CET) at the company's office in Frysjaveien 40, entrance 12, 4th floor, 0884 Oslo, Norway.
The notice includes, in addition to approval of the annual accounts for the financial year 2010, and other customary matters for the ordinary general meeting, a proposal to replace the board authorization to purchase own shares within a maximum limit of 10% of the share capital pursuant to Chapter 9 of the Norwegian Public Limited Companies Act. Furthermore, the Board proposes that the General Meeting resolves to replace the current Board authorization to increase the share capital by granting the Board a new authorization to increase the share capital by up to NOK 6,860,314.50, equivalent to 10% of the current share capital. The new Board authorization will enable the Company to issue shares in relation to private placements, strategic partnerships, acquisitions, mergers, stock option plans for the company's management, employees and key personnel, or for the purpose of strengthening the company's financial position, without having to call for a General Meeting prior to such share issue.
The General Meeting will also resolve on the election of board members. The term of service for the Chairman of the Board Robert V. Ahlgren and the board member  Mathias Uhlen expires at the date of the Annual General Meeting. The Nomination Committee proposes that the Chairman of the Board Robert V. Ahlgren and the board member Mathias Uhlen are reappointed for terms of two years and one year, respectively.
Furthermore, the General Meeting is asked to resolve on the proposal that Ann-Kristin Hageløkken is appointed as new Chairperson of the Company's Nomination Committee, replacing Frode Vaksvik. Hageløkken is proposed to be appointed for a term of two years until the Annual General Meeting in 2013.
The annual report for 2010 was released in a stock exchange notice March 29 2011 and is also submitted by mail to the shareholders along with the notice, including attachments.
Complete notice is attached.
CEO Mårten Wigstøl            Phone +47 911 65775
CFO Tone Kvåle                 Phone +47 915 19576       
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 41.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information -

Find the Notice of Annual General Meeting and the Annual Report 2010 here

Read the Notice in Norwegian here